{"id":"cancervax-vaccine-canvaxin","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CANVAXIN is an autologous whole-cell vaccine derived from two human melanoma cell lines that express common tumor-associated antigens (MAGE-1 and MAGE-3). It is designed to activate T-cell mediated immunity against melanoma cells expressing these antigens, enabling the patient's immune system to target and eliminate cancer cells. The vaccine approach aims to provide durable anti-tumor immunity by priming cytotoxic T lymphocytes.","oneSentence":"CANVAXIN is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:49.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (adjuvant setting)"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT01546571","phase":"PHASE3","title":"Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients","status":"TERMINATED","sponsor":"Polynoma LLC","startDate":"2012-05-01","conditions":"Melanoma","enrollment":504},{"nctId":"NCT00101166","phase":"PHASE2","title":"Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2004-10","conditions":"Melanoma (Skin)","enrollment":43},{"nctId":"NCT00004104","phase":"PHASE2","title":"Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"1998-06","conditions":"Melanoma (Skin)","enrollment":""},{"nctId":"NCT00128583","phase":"PHASE2","title":"Vaccine Therapy in Treating Patients With Malignant Melanoma","status":"UNKNOWN","sponsor":"CancerVax Corporation","startDate":"2005-07","conditions":"Melanoma (Skin)","enrollment":""},{"nctId":"NCT00928902","phase":"PHASE2","title":"Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma","status":"COMPLETED","sponsor":"University of Virginia","startDate":"1999-11","conditions":"Melanoma","enrollment":41},{"nctId":"NCT00052130","phase":"PHASE3","title":"Vaccine Therapy for Patients With Stage III Melanoma","status":"UNKNOWN","sponsor":"CancerVax Corporation","startDate":"","conditions":"Malignant Melanoma","enrollment":1118},{"nctId":"NCT00052156","phase":"PHASE3","title":"Vaccine Therapy for Patients With Stage IV Melanoma","status":"UNKNOWN","sponsor":"CancerVax Corporation","startDate":"","conditions":"Malignant Melanoma","enrollment":670}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CancerVax vaccine (CANVAXIN)","genericName":"CancerVax vaccine (CANVAXIN)","companyName":"CancerVax Corporation","companyId":"cancervax-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"CANVAXIN is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Melanoma (adjuvant setting), Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}